Kaibori, Masaki
Sakai, Kazuko
Matsushima, Hideyuki
Kosaka, Hisashi
Matsui, Kosuke
De Velasco, Marco A.
Sekimoto, Mitsugu
Nishio, Kazuto http://orcid.org/0000-0002-8275-0846
Funding for this research was provided by:
japan society for the promotion of science (JP19K07722)
Article History
Received: 4 August 2021
Accepted: 12 November 2021
First Online: 1 January 2022
Declarations
:
: Kazuko Sakai reports personal fees from AstraZeneca, Bio-Rad Laboratories, Chugai Pharmaceutical, Roche Diagnostics, Hitachi, outside the submitted work. Kazuto Nishio reports grants and personal fees from Eli Lilly, Nippon Boehringer Ingelheim, grants from Ignyta, Korea Otsuka Pharmaceutical, Thoracic Oncology Research Group, North East Japan Study Group, and personal fees from Chugai Pharmaceutical, Eisai, Pfizer, Novartis Pharma, MSD, Ono Pharmaceutical, Bristol-Myers Squibb, SymBio Pharmaceuticals, Life Technologies Japan, Solasia Pharma, Yakult Honsha, Roche Diagnostics, AstraZeneca, Otsuka Pharmaceutical, Sanofi, Guardant Health, Amgen, outside the submitted work. Marco A. De Velasco has received financial and material research support from AstraZeneca, Janssen and Taiho Pharmaceutical outside the submitted work. Masaki Kaibori, Hideyuki Matsushima, Hisashi Kosaka, Kosuke Matsui, and Mitsugu Sekimoto declare no conflicts of interest.
: Not applicable.
: Not applicable.
: Not applicable.
: This study was conducted in compliance with the Helsinki Declaration and the ethical guidelines for medical and health research involving human subjects in Japan. This study was approved by the institutional ethics review boards of Kansai Medical University Hospital (#1429) and Kindai University, Faculty of Medicine (27-033).
: Yes.